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Abstract
Background: Predictive modeling presents an opportunity to contain the expansion of medical expenditures by
focusing on very few people. Evaluation of how risk adjustment models perform in predictive modeling in Taiwan
or Asia has been rare. The aims of this study were to evaluate the performance of different risk adjustment models
(the ACG risk adjustment system and prior expenditures) in predictive modeling, using Taiwan’s National Health
Insurance (NHI) claims data, and to compare characteristics of potentially high-expenditure subjects identified
through different models.
Methods: A random sample of NHI enrollees continuously enrolled in 2002 and 2003 (n = 164,562) was selected.
Health status measures and total expenditures derived from 2002 NHI claims data were used to predict the
possibility of becoming 2003 top users. Statistics-based indicators (C-statistics, sensitivity, & Predictive Positive Value)
and characteristics of identified top groups by different models (expenditures and prevalence of manageable
diseases) were presented.
Results: Both diagnosis-based and prior expenditures models performed much better than the demographic
model. Diagnosis-based models were better in identifying top users with manageable diseases; prior expenditures
models were better in statistics-based indicators and identifying people with higher average expenditures. Prior
expenditures status could correctly identify more actual top users than diagnosis-based or demographic models.
The proportions of actual top users that could be identified by diagnosis-based models alone were much lower
than that identified by prior expenditures status.
Conclusions: Predicted top users identified by different models have different characteristics and there is little
agreement between modes regarding which groups would be potentially top users; therefore, which model to use
should depend on the purpose of predictive modeling. Prior expenditures are a more powerful tool than
diagnosis-based risk adjusters in terms of correctly identifying more actual high expenditures users. There is still
much room left for improvement of diagnosis-based models in predictive modeling.
Background
Research analyzing the distribution of medical expendi-
tures has consistently shown that a large proportion of
medical resources are consumed by a small percentage
of the total population[1]. The top 20% of the
population with the highest expenditures accounted for
about 80% of all healthcare expenditures in the United
States[2-4]. This phenomenon of the concentration of
healthcare expenditures has been observed continuously
since 1970[5]. Consequently, this group of extraordina-
rily high users of medical resources has inevitably
become a target of several types of cost-containment
strategies, such as disease management, care manage-
ment, and utilization review[1,6].
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as ‘a process of applying existing patient data to pro-
spectively identify persons with high medical needs who
are at risk for higher future medical utilization[7].’ Pre-
dictive modeling is important because early intervention
can be delivered to persons identified as possibly having
high medical needs. By helping these individuals manage
their diseases effectively and providing coordinated med-
ical care, their medical utilization can be reduced and
the quality of care they receive can be maintained or
improved[8]. In the long run, the expansion of medical
expenditures may be controlled within a reasonable
range[4,6]. Diagnosis-based health indicators and prior
expenditures are the two most common types of risk
adjusters for this purpose. It was found that both types
of models were very comparable in overall discrimina-
tion (by C-statistics), sensitivity, and specificity; however,
high-expenditure individuals identified by diagnosis-
based models had higher disease burden and somewhat
higher healthcare utilization[3,8-10]. Since high-expendi-
ture users identified by diagnosis-based models have
more ‘manageable’ diseases that are targets of disease
management programs, it is the preferred model to use.
Taiwan launched a government-run, single-payer
National Health Insurance (NHI) programme in May
1995. All Taiwanese nationals are obligated by law to
join this programme to ensure adequate risk pooling.
Under the jurisdiction of the national government’s
Department of Health, the NHI is administered by the
Bureau of National Health Insurance (BNHI) and six
regional branches are in charge of administrating the
NHI in each area. The NHI’s benefit packages are com-
prehensive, including inpatient and outpatient services,
pharmacy services, Chinese medicine and dental ser-
vices. Beneficiaries have complete freedom of choice of
providers and therapies, and they do not need to go
through ‘gatekeepers’ in order to obtain medical services
from specialists. The primary source of funding for the
NHI is the payment of premiums shared by the insured,
the employers and the government. In terms of reim-
bursement, the global budget payment system was
adopted in order to contain the growth of medical
expenditure. Within budget limits, the NHI reimburses
contracted providers mostly on a fee-for-service basis,
using uniform national fee schedules.
Given the rising concerns to contain the growth of
medical expenditures, predictive modeling presents an
opportunity to achieve this goal by focusing on very few
people. However, previous studies regarding predictive
modeling have used regional datasets or focused only on
sub-populations, and werec o n d u c t e di nt h eW e s t e r n
countries. Taiwan is one of very few healthcare systems
in the world which has universal coverage and a single
national computerized database that includes medical
diagnosis information on almost 100% of the population.
For this reason the results of this paper have potential
policy and methodology implications for most other
high or middle income nations.
Few studies related to predictive modeling have been
conducted in Taiwan. It has been shown that a govern-
ment-sponsored disease-management program signifi-
cantly reduced medical utilization for patients with
asthma[11]. In addition, patients in the program had
more accurate knowledge of and better self-care skills
concerning asthma, and were more likely to adhere to
physicians’ suggestions[11]. These achievements imply
that medical expenditures incurred by this group of
patients could potentially be reduced by providing dis-
ease and care management, while quality of care could
be improved. Utilization review has also been imple-
mented by the Bureau of National Health Insurance
(BNHI) in Taiwan, but it was done retrospectively;
under such situation, high-expenditure users could only
be identified after a large amount of expenditures had
occurred, and only a certain proportion of this popula-
tion would remain high-expenditure users in the follow-
ing years.
The goal of this study is to evaluate the performance
of the Adjusted Clinical Group (ACG) risk adjustment
system in predictive modeling using Taiwan’sN a t i o n a l
Health Insurance claims data, and to compare character-
istics of potentially high-expenditure subjects identified
through different models.
Methods
Data sources
The source of the data was a longitudinal dataset pre-
pared by Taiwan’s Bureau of National Health Insurance,
which is available for researchers interested in observing
longitudinal changes of medical utilization. This dataset
contained enrollment and claims files of a randomly
chosen 1% of Taiwan’s population (~200,000 indivi-
duals). The enrollment files contained individual sub-
scription information and demographic factors,
including sex, date of birth, type of beneficiaries, and
location. The claims files contained comprehensive
records of inpatient care, ambulatory care, pharmacy
store, dental care, and Chinese medicine services. The
files also included date of service, ICD-9-CM (Interna-
tional Classification of Diseases) diagnosis codes,
claimed medical expenses, and amount of co-payment
for each encounter. Twenty-four-month enrollment in
both years (2002 and 2003) was required for this analy-
sis, resulting in the final sample size of 164,562 subjects.
Individuals’ identifiers in this dataset have been
encrypted to protect privacy and confidentiality, and this
study has been approved by the Johns Hopkins School
of Public Health Institutional Review Board.
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were aggregated from all inpatient, outpatient, and phar-
macy store claimed expenses, including claimed reim-
bursement, medication expenses, and co-payments.
Expenses for dental care and Chinese medicine were
excluded from this aggregation. Both 2002 and 2003
expenditures were calculated. The unit of money in Tai-
wan is New Taiwan Dollar (NTD); the exchange rate is
about 31 NTD: 1 US dollar as of May 2010. Demo-
graphic factors included sex, categorical age (0-17, 18-
34, 35-49, 50-64, ≧65), type of beneficiary (insured or
dependent), insurance category (based on insured’s type
of job), residence (three levels with different degrees of
population density), and locality (six geographic regions
by BNHI’s administrative branches: Taipei, Northern,
Central, Southern, Kao-Ping, Eastern). Diagnosis-based
risk adjustment factors, including ACG, ADG (Aggre-
gated Diagnosis Group) and EDC (Expanded Diagnosis
Cluster), were derived from the ACG case-mix system
(Version 7.1) using individuals’ overall ICD-9-CM codes
from both inpatient and outpatient records (diagnosis
codes from dental and Chinese medicine services were
excluded) in the year 2002.
The ACG risk adjustment system
ACGs are mutually exclusive health status categories
defined by morbidity pattern, age, and sex. The ACG
system assigns all ICD-9-CM codes to one of 32 diag-
nostic clusters (ADGs) based on five clinical dimensions:
duration, severity, diagnostic certainty, etiology, and spe-
cialty care involvement[12,13]. Each ADG is a grouping
of diagnosis codes similar in terms of severity and likeli-
hood of persistence of the health condition treated over
a relevant period. ADGs are not mutually exclusive and
individuals can have multiple ADGs (up to 32). Indivi-
duals are then placed into one of 93 discrete ACG cate-
gories according to their assigned ADGs, age, and sex;
the result is that individuals within a given ACG have
experienced a similar pattern of morbidity and resource
consumption. Expanded Diagnosis Clusters (EDCs) are
binary indicators to show whether an individual has spe-
cific diseases/symptoms. The EDC methodology assigns
each ICD code to a single EDC; there are 264 EDCs in
total. ICD codes within an EDC share similar clinical
characteristics and are expected to induce similar types
of diagnostic and therapeutic responses.
Risk adjustment models
Five risk adjustment models evaluated in this study are
listed below based on the comprehensiveness of risk
adjusters:
Model 1: Demographics (sex and age groups) only,
Model 2: ACGs with demographics,
Model 3: ADGs plus selected EDCs with demographics,
Model 4: Prior expenditures with demographics, and
Model 5: Prior expenditures, ADGs plus selected
EDCs with demographics.
Selected EDCs were derived from the results of step-
wise analyses in explaining prospective total expendi-
tures, using a full set of EDCs and a multivariate linear
regression model; 19 EDCs were thus chosen (Addi-
tional file 1).
Outcomes and measures of model performance
Being a high-expenditure user was a binary variable
defined using the following three thresholds: top 0.5%,
1%, and 5% users in 2003. We applied a logistic regres-
sion model, given that it is the standard approach to
analyze dichotomous outcomes. We conducted all statis-
tical analyses using SAS™ software version 9.1. Perfor-
mance of five risk adjustment models was evaluated
from three aspects: statistical indicators, proportions of
true cases identified by models, and characteristics of
predicted cases. Statistical indicators included C-statis-
tics, sensitivity, and predictive positive value[1], and the
thresholds for calculating statistical indicators were set
as the corresponding levels of outcomes. The c-statistic
represents the area under the Receiver Operating Char-
acteristic (ROC) curve, and hence provides an overall
measure of model performance; in addition, the c-statis-
tic is also independent of other conditions. Actual 2003
top users were assigned to one of four mutually exclu-
sive categories: in 2002 top user group alone, in pre-
dicted top user group identified by risk adjustment
models alone, in both groups, or in neither group
(Figure 1). The real contribution of risk adjustment
models comes from those identified by models alone,
because these subjects may not be known without
applying risk adjustment models (area a in Figure 1).
After a group of high-expenditure users was identified
by each model, it was also common to examine the
characteristics of this population as an alternative
method to assess the model performance. Expenditures-
based performance indicators included 2003 average
total and drug expenditures in the identified top groups,
top/bottom total and drug expenditures ratio (2003
average expenditures in top group divided by average
expenditures in the rest of the population), and year-2/
year-1 total and drug expenditures ratio (2003 average
expenditures divided by 2002 average expenditures in
top group)[9]. A better risk adjustment model will have
higher total and drug expenditures, higher top/bottom
expenditures ratio, and higher year-2/year-1 expendi-
tures ratio (subjects with expenditures increasing over
time are better targets for intervention). In addition, the
proportion of identified high-expenditure subjects with
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depression, or diabetes) is also another important indica-
tor and extensively used[3,10]. Split analysis (a randomly
selected 70% of study subjects were used for model devel-
opment; the rest were set aside for model validation) was
performed and measures of model performance were
obtained from the validation set to avoid overfitting.
Results
Characteristics of the population (Table 1)
About half of the study subjects were male and 40%
were insured. The mean age in 2002 was 35 years and
10% were elderly. About one-third lived in the areas
within the Taipei Branch; only 2% were from the East-
ern Branch. About 64% were living in rural county
areas. Only 10% had not made any outpatient visit; 7%
had at least one inpatient stay. About 90% had non-zero
total expenditures and a similar percentage had non-
zero drug expenditures. Average annual total expendi-
tures were about 14,700 NTDs, among which medical
expenditures (10,200 NTDs) were much high than phar-
macy expenditures (4,100 NTDs).
C-statistics, sensitivity, and positive predictive value
(Table 2)
A similar trend was observed across three outcome
thresholds (top 0.5%, 1%, and 5% of actual users): more
comprehensive models performed better than simpler
models in terms of C-statistics. The largest increase was
from model 1 to model 2 (~0.06 point), and then from
model 2 to model 3 (~0.04 point); the performance of
the most comprehensive three models were separated by
only 0.01 points. C-statistics in model 1 and 2 increased
while those in two prior expenditures models decreased
as outcome thresholds were relaxed; those in model 3
remained similar. When the outcome was defined as top
0.5%, 0.1% and 5% of actual 2003 users, c-statistics in
model 5 reached 0.913, 0.907, and 0.897, respectively;
those in model 1 were 0.773, 0.797 and 0.815,
correspondingly.
To calculate sensitivity and PPV, a threshold to define
top users was necessary. We used two thresholds in this
study for each outcome: the actual proportion of the
defined outcomes and the top 5% of identified cases.
Results showed that the stricter the threshold, the lower
the sensitivity but the higher the PPV. Similarly, sensi-
tivity and PPV went up as the comprehensiveness of the
model increased, regardless of outcomes or thresholds.
The biggest increase in sensitivity and PPV was from
model 2 to model 3, while those in model 4 and 5 were
close. When threshold cutoff points were fixed at the
top 5%, it showed that as outcome standards relaxed,
PPV increased across all models, but sensitivity
increased in the demographics-only model and reduced
in more comprehensive models.
Proportion of true cases identified by risk adjustment
models and prior top user status (Table 3 & Figure 1)
We examined three risk adjustment models that were not
related to prior expenditures, including model 1 to model
C B
A: Identified by Risk Adjustment Model Only
B: Identified by Both Risk Adjustment Model and Prior Cost Status
C: Identified by Prior Cost Status Only
D: Not Identified by Either Model
Actual Top Users
D A
Figure 1 Classification of actual top users.
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top users in the previous year (47.9%, 44.3%, and 47.6%
when the threshold for top users was set as 0.5%, 1%, and
5%, respectively). The proportion of true cases identified
by risk adjustment models (Figure 1: area a plus area b)
increased as the comprehensiveness of the risk adjustment
model increased, regardless of outcome standards. We
also found that the proportion of true cases that could be
identified by prior expenditures status was always larger
than that proportion by risk adjustment models (Figure 1:
area c > area a), especially in simple ones. In addition, the
proportion of true cases identified solely by risk adjust-
ment model (Figure 1: area a) was low, and the difference
between three models seemed to decrease as the outcome
standards relaxed. For example, among 2003 top 1% of
actual users, only 5.08% could be identified by the demo-
graphics model, 13.82% by model 2, 31.30% by model 3,
and the proportion identified by risk adjustment models
alone was much lower: 2.64%, 5.08%, and 6.10%,
respectively. Among 2003 top 5% of actual users, 25.78%
could be identified by the demographic model, 36.52% by
model 2 and 41.67% by model 3; the proportion that could
be identified by risk adjustment model alone was similar
across three models, 10.5%.
Characteristics of predicted cases by risk adjustment
models (Tables 4 &5)
Across three outcome standards, total expenditures,
drug expenditures, and top/bottom expenditures ratio
generally increased as the comprehensiveness of the risk
adjustment model increased. There was a large increase
in total expenditures, drug expenditures, and top/bot-
tom expenditures ratios from model 1 to model 2, and
from model 2 to model 3; two models with prior expen-
ditures stayed relatively the same. For example, when
the outcome was the 2003 top 1% of actual users, the
average total expenditures of the predicted top 1% of
users increased from 54,520 NTDs in model 1 to
220,395 NTDs in model 3, and then to 262,609 NTDs
in model 5. Top/bottom total expenditures ratio
increased from 3.8 in model 1 to 18 in model 3, and
then to 22 in prior expenditures models (model 4 and
5); top/bottom drug expenditures ratio increased from
4.2 in model 1 to 9.5 in model 3, and then to 16.5 in
prior expenditures models. In terms of year-2/year-1
expenditures ratio, model 1 had the highest ratio among
all (1.2), model 3 had total expenditures ratio about one,
while those of the remaining models were all smaller
than one, especially in model 4 and 5 (0.8 ~ 0.9).
As the outcome standard was relaxed from the top
0.5% to the top 5%, there was a general trend for average
total and drug expenditures in identified top groups by
different models to decrease. Such a decreasing trend
became more obvious as the comprehensiveness of risk
adjusters increased. For example, the average total expen-
ditures in the demographically-identified top group
decreased from 58,000 to 51,590 NTDs, but in the top
groups identified by model 5 it decreased from 391,583
to 111,235 NTDs. In addition, the top/bottom expendi-
tures ratio was much higher in total expenditures than in
drug expenditures when the outcome was set at the top
0.5% in all but the demographics model (30.7 for total
expenditures and 19.3 for drug expenditures in model 5);
when the outcome was set at the top 5%, however, the
top/bottom drug expenditures ratio was comparable to
or higher than the total expenditures ratio (11.6 for total
expenditures and 12.6 for drug expenditures in model 5).
In addition to expenditures, we examined the preva-
lence of five commonly manageable diseases (asthma,
hypertension, depression, COPD, and diabetes) among
predicted top groups (Table 5). Across three outcome
levels, predicted top groups identified by diagnosis-
Table 1 Characteristics of the Taiwanese population for
prospective analyses
Inclusion Criteria 2002 & 2003
24 month enrollment
Number of observations 164,562
Male 49.35%
The Insured* 40.93%
Mean age in 2002 34.98
Age Group in 2002
0 ~ 17 23.84%
18 ~ 34 26.83%
35 ~ 49 25.51%
50 ~ 64 14.19%
≥65 9.62%
BNHI Branch
Taipei 32.52%
Northern 14.81%
Central 19.94%
Southern 14.42%
Kao-Pin 16.03%
Eastern 2.27%
Residence Level
Special Municipality 21.31%
City 15.13%
County 63.56%
Medical Utilization
≥1 outpatient visit 89.71%
≥1 inpatient time 7.17%
≥1 pharmacy expenditures 87.77%
≥1 total expenditures 90.05%
Total expenditures (NTD/yr) 14,741
Medical expenditures (NTD/yr) 10,214
Pharmacy expenditures (NTD/yr) 4,108
*: There are two types of beneficiaries: the insured and the dependent. The
dependent obtained its health insurance coverage through the insured.
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Page 5 of 11Table 2 C-Statistics, sensitivity, and positive predictive value by five risk adjustment models and three outcome
thresholds
Model 1:
Demo (sex,
ages)
Model 2:
ACGs &
Demo
Model 3:
ADGs, Sel. EDCs &
Demo.
Model 4:
2002 expenditures &
Demo.
Model 5:
ADGs, Sel. EDCs, 2002
expenditures & Demo.
Outcome: 2003 top 0.5% user (N = 242)
C-Statistics 0.773 0.849 0.893 0.904 0.913
Top 0.5% predicted
group
%
identified
0.52% 0.49% 0.48% 0.49% 0.48%
sensitivity 0.021 0.037 0.343 0.450 0.450
PPV 0.019 0.037 0.347 0.447 0.456
Top 5% predicted
group
%
identified
5.03% 4.85% 4.89% 4.94% 4.83%
sensitivity 0.169 0.360 0.665 0.698 0.707
PPV 0.017 0.036 0.067 0.069 0.072
Outcome: 2003 top 1% user (N = 492)
C-Statistics 0.797 0.860 0.893 0.900 0.907
Top 1% predicted
group
%
identified
0.98% 0.98% 1.01% 1.00% 0.99%
sensitivity 0.051 0.138 0.313 0.396 0.402
PPV 0.051 0.140 0.310 0.396 0.403
Top 5% predicted
group
%
identified
4.84% 4.86% 4.88% 4.94% 4.89%
sensitivity 0.228 0.384 0.598 0.622 0.650
PPV 0.047 0.079 0.122 0.125 0.133
Outcome: 2003 top 5% user (N = 2,467)
C-Statistics 0.815 0.869 0.884 0.885 0.897
Top 5% predicted
group
%
identified
4.89% 4.89% 4.97% 4.89% 4.93%
sensitivity 0.258 0.365 0.417 0.467 0.476
PPV 0.264 0.373 0.419 0.477 0.482
Demo: demographic information (sex and age groups); PPV: positive predictive value
Table 3 Proportion of true cases identified by ACG models and prior expenditures status at three outcome thresholds
Model 1:
Demographics
Model 2:
ACGs &
Demographics
Model 3:
ADGs, Sel., EDCs &
Demographics
Among 2003 top 0.5% user (N = 242)
Top 0.5% predicted
group
In top 0.5% predicted group only
(area A*)
2.07% 2.89% 5.79%
In both groups (area B*) 0.00% 0.83% 28.51%
In 2002 top 0.5% users only (area C*) 47.93% 47.11% 19.42%
Among 2003 top 1% user (N = 492)
Top 1% predicted group In top 1% predicted group only (area
A*)
2.64% 5.08% 6.10%
In both groups (area B*) 2.44% 8.74% 25.20%
In 2002 top 1% users only (area C*) 41.87% 35.57% 19.11%
Among 2003 top 5% user (N = 2,467)
Top 5% predicted group In top 5% predicted group only (area
A*)
10.50% 10.58% 10.82%
In both groups (area B*) 15.28% 25.94% 30.85%
In 2002 top 5% users only (area C*) 32.27% 21.61% 16.70%
*: in Figure 1
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manageable diseases than the actual top groups. Those
identified by diagnosis-based models had the highest
number of manageable conditions compared to models
including prior expenditures. On average, the predicted
top 0.5% and 1% group by model 2 had 1.33 and 1.35
conditions, respectively; the predicted top 5% group by
model 3 had 1.46 conditions; the predicted top groups
by the demographic model had the lowest number of
conditions across three outcome levels (all less than 1).
When looking at specific conditions, the predicted top
groups by diagnosis-based only model generally had
higher prevalence of asthma, hypertension, and COPD;
those by models including prior expenditures usually
had higher prevalence of depression. For example,
among the predicted top 1% groups, the prevalence of
asthma, hypertension, and COPD were highest in the
ACG-identified groups, reaching 14%, 55.5%, and 30%,
respectively; the prevalence of depression was highest in
the group identified by the model 5, reaching 8.8%. In
addition, other than model 1 and 2, the predicted top
groups by the remaining three models had higher preva-
lence of five conditions as the outcome threshold
relaxed. For example, among the top groups identified
Table 4 Expenditure-related characteristics of predicted top user groups identified by five risk adjustment models at
three outcome thresholds
Model 1:
Demographics
Model 2:
ACGs &
Demographics
Model 3:
ADGs, Sel. EDCs
& Demographics
Model 4:
2002 Expenditures
& Demographics
Model 5:
ADGs, Sel. EDCs, 2002
Expenditures &
Demographics
Outcome: 2003 top 0.5% user
predicted top
0.5% user group
2003 average total
expenditures
58,136 108,433 303,755 389,851 391,583
2003 average drug
expenditures
16,706 29,255 41,282 72,792 72,189
Top/bottom total
expenditures ratio
4.1 7.7 23.1 30.7 30.7
Top/bottom drug
expenditures ratio
4.2 7.4 10.6 19.5 19.3
2003/2002 total
expenditures ratio
1.26 0.88 1.03 0.74 0.80
2003/2002 drug
expenditures ratio
1.18 0.88 0.85 0.81 0.84
Outcome: 2003 top 1% user
predicted top
1% user group
2003 average total
expenditures
54,520 114,802 220,395 268,398 262,609
2003 average drug
expenditures
16,595 29,367 35,640 59,512 56,430
Top/bottom total
expenditures ratio
3.8 8.5 17.7 22.3 21.7
Top/bottom drug
expenditures ratio
4.2 7.7 9.5 16.9 15.9
2003/2002 total
expenditures ratio
1.20 0.93 1.00 0.76 0.80
2003/2002 drug
expenditures ratio
1.17 0.90 0.89 0.86 0.88
Outcome: 2003 top 5% user
predicted top
5% user group
2003 average total
expenditures
51,590 78,295 96,411 110,795 111,235
2003 average drug
expenditures
16,564 23,136 26,830 32,839 32,770
Top/bottom total
expenditures ratio
4.1 6.9 9.4 11.5 11.6
Top/bottom drug
expenditures ratio
4.8 7.5 9.3 12.6 12.6
2003/2002 total
expenditures ratio
1.15 0.99 1.00 0.88 0.91
2003/2002 drug
expenditures ratio
1.09 1.02 1.03 0.98 0.99
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increased from 1.16, 1.27, to 1.29 while the threshold
was set as 0.5%, 1%, and 5%, correspondingly.
Among the predicted top groups across all outcome
thresholds and diagnosis-based/prior-expenditures risk
adjustment models (demographic model not included),
hypertension was the most prevalent condition, with
more than 50% having hypertension; diabetes was the
second, with about 30%; the third was COPD, ranging
from 20% to 30%; ~10% had asthma, and somewhat
fewer than 10% had depression.
Discussion
The results showed that both diagnosis-based and prior
expenditures models performed much better than
demographic models in predictive modeling, based on
virtually all measures evaluated in the study (statistics-
based indicators, expenditures indicators, and prevalence
of manageable diseases in top groups identified by mod-
els). Diagnosis-based models performed better in identi-
fying high-expenditure users with manageable diseases;
prior expenditures models were better in statistics-based
indicators and identifying people with higher average
expenditures. Prior expenditures status could correctly
identify more actual high-expenditure users than diag-
nosis-based or demographics models. The proportions
of true high-expenditure users that could be identified
by diagnosis-based models alone were much lower than
that by prior expenditures status.
In Taiwan, the degree of the concentration of medical
expenditures on a small group is comparable to what
has been observed in the United States: the top 0.5%
consumed somewhat more than 20%, the top 1% con-
sumed about 30%, while the top 5% consumed more
than 50% of total medical expenditures. However, the
next-year medical expenditures incurred by current
high-expenditure users was much higher in Taiwan
compared to the United States: in Taiwan, the year 1
top 0.5% group consumed 21.09% in current year and
14.53% in year 2; in the United States, the comparable
group consumed about 20% and 7%, respectively. In
addition, prior expenditures were also strongly related
to current expenditures (Pearson’s correlation coefficient
between 2002 and 2003 total expenditures: 0.64), and
about 50% of high-expenditure users in 2002 remained
so in 2003. Therefore, the performance of models
including prior expenditures should be better in Taiwan
than in the United States. This strong correlation also led
Table 5 Prevalence of selected diseases among predicted top user groups by five risk adjustment models at three
outcome thresholds
Actual Top
Users
Model 1:
Demographics
Model 2:
ACGs &
Demographics
Model 3:
ADGs, 19 EDCs &
Demographics
Model 4:
2002 Expenditures &
Demographics
Model 5:
ADGs, 19 EDCs, 2002
Expenditures & Demographics
2003 Top 0.5% predicted user
#o f
Conditions
0.963 0.988 1.329 1.238 1.160 1.251
Asthma 7.85% 9.27% 12.76% 8.37% 10.25% 8.79%
Hypertension 42.98% 45.56% 55.14% 57.32% 50.82% 54.81%
Depression 6.20% 1.93% 5.35% 3.35% 7.79% 7.95%
Diabetes 21.07% 19.31% 27.57% 33.89% 27.46% 33.05%
COPD 18.18% 22.78% 32.10% 20.92% 19.67% 20.50%
2003 Top 1% predicted user
#o f
Conditions
0.967 0.971 1.351 1.256 1.270 1.271
Asthma 9.55% 7.61% 14.02% 10.26% 11.99% 11.81%
Hypertension 41.67% 46.91% 55.46% 54.33% 53.05% 52.95%
Depression 6.50% 2.67% 7.63% 7.85% 6.71% 8.76%
Diabetes 20.93% 20.16% 27.84% 30.38% 29.27% 31.57%
COPD 18.09% 19.75% 30.10% 22.74% 26.02% 22.00%
2003 Top 5% predicted user
#o f
Conditions
1.030 0.981 1.283 1.459 1.288 1.425
Asthma 9.00% 7.50% 11.84% 12.52% 10.39% 12.17%
Hypertension 44.83% 48.38% 57.99% 66.33% 59.73% 64.45%
Depression 6.24% 2.40% 6.13% 8.40% 6.00% 8.30%
Diabetes 26.27% 21.14% 26.78% 34.53% 29.88% 34.32%
COPD 16.62% 18.70% 25.54% 24.13% 22.85% 23.22%
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including prior expenditures had higher prior expenditures
than those identified by models without prior expendi-
tures. In this study, their year 2 expenditures were higher
than year 1, so that it showed a trend of decreasing expen-
ditures over time. Users with expenditures decreasing over
time may not be good candidates for interventions because
their expenditures are going down already without inter-
ventions; they may not even need interventions to bring
down their medical expenditures.
On the contrary, diagnosis-based models are better in
catching people with ‘manageable’ conditions and those
with increasing expenditures trends. It is critical that
subjects predicted to be high-expenditure cases by mod-
els are “intervenable” so that their health status and
medical utilization can possibly be improved and con-
trolled through managed care or disease management
programs. For example, an individual with a serious car
accident will have very high medical expenditures in
year 1, and will be predicted to be a high-expenditure
user in year 2 if prior expenditures are included in the
model. It is of little use to identify such a person
because nothing much can prevent a car accident from
happening (assuming car accidents occur by chance),
and his/her medical expenditures will go down naturally
in the following year without any intervention.
Part of the reason that the diagnosis-based model is
better in catching more people with selected conditions
is endogeneity. All five ‘manageable’ conditions were
chronic, and individuals with any of the five conditions
were more than likely to have condition-related diagno-
sis codes on their medical records over a yearly period.
Individuals with claims data containing diagnosis codes
related to these five conditions were then used as input
for diagnosis-based risk adjustment models to identify
high-expenditure users. Since patients with any of the
five conditions were more likely to consume more
resources, they were more likely to be included in iden-
tified top groups. And then, the same diagnosis codes
were again used to distinguish whether identified sub-
jects had these five conditions.
Without risk adjustment models, the best that health
plans can do to identify potentially high-expenditure
users is to rely on prior expenditures status. Therefore,
the value of risk adjustment models partially lies in the
ability to discover what otherwise would not have been
found if risk adjustment models were not used. Overall,
diagnosis-based models correctly identify a much higher
number of high-expenditure users than the demographic
model. However, the proportion of actual top users that
can be identified solely by diagnosis-based risk adjust-
ment models is only slightly more than what the demo-
graphic model can achieve. This is mainly due to the
fact that there is a much higher overlap of top predicted
groups between diagnosis-based models and prior expen-
ditures status compared to that between the demographic
model and prior status (area b in Figure 1). Even though
diagnosis-based models do not outperform demographic
models in identifying more top users with the existence
of prior expenditures information, diagnosis-based
models are still better choices given the ability to identify
subjects with more ‘manageable’ conditions and higher
total expenditures.
It has been shown in the United States that there is little
agreement between different models regarding who is
identified as top users[3,8-10,14,15]. For example, only
0.19% of total subjects are identified as top users in both
prior expenditures and diagnosis-based (DCGs) models
when the outcome is set as the top 0.5% (the perfect
match would lead to 0.5%)[3]. In Taiwan, the same phe-
nomenon also exists (Table 6). Taking the top 0.5% as an
example, the overlap of identified top users between two
diagnosis-based models was only 0.07% while that between
two models including prior expenditures was also not per-
fect (only 0.36%). The overlap between the prior expendi-
tures and the comprehensive diagnosis model was 0.19%.
Given that there is little overlap and that top groups iden-
tified by different models have different characteristics, it
is important for policymakers to clarify what the purpose
of predictive modeling is before they make decisions on
which model to use. If higher total expenditures is pre-
ferred, it is crucial to include prior expenditures in the
model; if more manageable diseases are preferred, a diag-
nosis-based model will be more effective.
Limitations
Predictive modeling presents an opportunity to reduce
medical expenditures by identifying a very small number
of potential top users regarding whom health plans can
take actions. Therefore, identifying potentially top users is
only the first step; what will be done after that also plays
an important role in determining how much reduction in
medical expenditures can possibly be achieved. No matter
how perfect the risk adjustment models can be in identify-
ing high-expenditure users, if no effective programs are
implemented, the ultimate goal of containing the expan-
sion of medical expenditures will not be realized.
The ACG risk adjustment system was developed using
U.S. data; it was not calibrated for how the healthcare
system works in Taiwan, so the system may not fit Tai-
wan’s claims data well. However, in prior research it has
been shown that the performance of the ACG system in
explaining medical utilizati o ni nT a i w a nw a ss i m i l a rt o
that in other countries[16-18]. In addition, it was also
assumed that the claims data obtained from BNHI
would be comprehensive enough to capture all impor-
tant diagnosis codes that may affect the patients’ mor-
bidity status. Given comprehensive benefits, easy access
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Page 9 of 11to medical care and the low cost of seeking care under
NHI, this may not be a big concern in the study.
Future Research Directions
Many risk adjusters can be used for predictive modeling;
however, in this study we included only diagnosis informa-
tion and prior expenditures. Other than diagnosis infor-
mation, drug information was also readily available in
Taiwan. Therefore, it will be interesting to evaluate how
much the performance of risk adjustment models will
improve once pharmacy information is also included. It is
also better if the model can identify a group of top users
with consistently high expenditures over time because it
takes time for interventions to show their effectiveness. So,
to analyze medical expenditures incurred by predicted top
groups from different models–not only in the next year
but also several years after–is an important next step to
evaluate how risk adjustment models really work.
Conclusions
Predicted top groups identified by different models have
different characteristics and there is little agreement
between modes regarding who would be potentially top
users. Diagnosis-based models tend to identify people with
more ‘manageable’ diseases; models with prior expendi-
tures are more likely to identify people with higher expen-
ditures. Therefore, which model to use should depend on
the purpose of the application. The prior expenditures
approach is a more powerful tool than diagnosis-based
risk adjusters in terms of correctly identifying actual high-
expenditure users. The proportions of actual top users
that can be identified by diagnosis-based risk models alone
are much lower than those by prior expenditures status
alone. There is still much room left for improvement of
diagnosis-based models in predictive modeling.
Additional material
Additional file 1: Process of generating selected EDCs (Expanded
Diagnosis Clusters). Describe the process of selecting 19 EDCs for
predictive modeling in model 3 & 5.
List of abbreviations
ACG: Adjusted Clinical Group; ADG: Aggregated Diagnosis Group; EDC:
Expanded Diagnosis Cluster; BNHI: Bureau of National Health Insurance; ICD:
Table 6 Overlap of top predicted groups by different risk adjustment models
Model 1:
Demographics
Model 2:
ACGs &
Demographics
Model 3:
ADGs, Sel. EDCs &
Demographics
Model 4:
2002 Expenditures &
Demographics
Model 5:
ADGs, Sel. EDCs, 2002
Expenditures & Demographics
2003 Top 0.5% Predicted User
Demographics 0.49%* 0.10% 0.03% 0.03% 0.02%
ACGs & Demographics 0.50% 0.07% 0.08% 0.06%
ADGs, 19 EDCs &
Demographics
0.50% 0.19% 0.29%
2002 Expenditures &
Demographics
0.50% 0.36%
ADGs, 19 EDCs, 2002
Expenditures & Demographics
0.50%
2003 Top 1% Predicted User
Demographics 1.00% 0.21% 0.11% 0.15% 0.11%
ACGs & Demographics 1.00% 0.30% 0.30% 0.32%
ADGs, 19 EDCs &
Demographics
1.00% 0.40% 0.65%
2002 Expenditures &
Demographics
1.00% 0.69%
ADGs, 19 EDCs, 2002
Expenditures & Demographics
1.00%
2003 Top 5% Predicted User
Demographics 4.96%* 2.43% 2.09% 2.46% 2.01%
ACGs & Demographics 5.00% 3.43% 3.02% 3.21%
ADGs, 19 EDCs &
Demographics
5.00% 3.09% 4.06%
2002 Expenditures &
Demographics
5.00% 3.73%
ADGs, 19 EDCs, 2002
Expenditures & Demographics
5.00%
*: There were several observations with exactly the same predicted value at the threshold.
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Page 10 of 11International Classification of Diseases; NTD: New Taiwan Dollar; PM:
predictive modeling; PPV: positive predictive value
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